SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending due to escalating geopolitical tensions in the Middle East, specifically following reports of US-Israeli strikes on Iran, which is fueling intense community debate about potential oil supply disruptions, particularly through the Strait of Hormuz. Investors are sharply divided between anticipating a significant oil price spike and expecting a 'sell the news' reversal.

Codatta

XNY (Codatta) is drawing significant attention for its strong performance and resilience, often showing green metrics even when the broader crypto market faces pullbacks. The community is actively discussing its potential for further breakouts and new highs, driven by its utility in powering AI and decentralized science data projects, alongside recent exchange listings.

ProShares Trust - ProShares Ultra Gold 2x Shares

ProShares Ultra Gold

UGL is trending as escalating geopolitical uncertainties and concerns over ongoing fiat currency debasement spur significant safe-haven demand, with the community actively discussing gold's strong upward momentum and the broader precious metals rally.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund is surging as escalating Middle East tensions, including strikes on oil infrastructure and disruptions to the Strait of Hormuz, fuel community expectations of significant oil price spikes and a massive upward move for the sector.

The centrifuge token model powers centrifuge, providing the framework needed to run the platform without reliance on a single point of failure, including the centrifuge team or Company, and to accelerate its utility. To accomplish this, centrifuge leverages the cryptoeconomic primitives of a native token called the centrifuge token (cfg), a nominated-proof-of-stake consensus algorithm that employs centrifuge to stake value, rewards for centrifuge adoption, and an on-chain governance mechanism that empowers centrifuge holders to guide the development of centrifuge.

Centrifuge

Centrifuge is trending following the launch of the world's first licensed S&P 500 Index Fund Token, a development hailed by the community as a monumental step for institutional adoption and a significant advancement in tokenizing real-world assets.

Wheaton Precious Metals Corp. is a precious metals streaming company with the quality portfolio of long-life, low-cost assets. Its business model offers investors commodity price leverage and exploration upside but with a much lower risk profile than a traditional mining company. It operates through the following business segments: Gold, Silver, Palladium, Cobalt, and Other. Wheaton was founded by Peter Derek Barnes on December 17, 2004 and is headquartered in Vancouver, Canada.

Wheaton Precious Metals Corp

Wheaton Precious Metals is gaining attention amid soaring gold prices reaching all-time highs and silver breaking multi-decade resistance, amplifying interest in its asset-light streaming model. The community is discussing recent strong earnings, a robust balance sheet, and a series of analyst target increases, though some express skepticism about its short-term price movements relative to the broader precious metals sector.

OR Royalties, Inc. engages in the acquisition, mining, and exploration of precious metals, streams, and other royalties. It holds interests in the Canadian Malartic mine. The company was founded on April 29, 2014 and is headquartered in Montreal, Canada.

OR Royalties Inc.

Osisko Gold Royalties Ltd

Osisko Gold Royalties is attracting significant community interest following its joint acquisition of a major gold stream on SolGold's Cascabel project and the emergence of activist investor Elliott Management as a large stakeholder. This news, combined with robust preliminary Q2 results showcasing record cash margins, reinforces bullish sentiment for the stable gold royalty player.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

GUSH is trending amid heightened speculation surrounding escalating Middle East geopolitical tensions and their potential impact on global oil supply routes, with the community actively discussing a significant upward move for oil and gas exploration and production.

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc

Aardvark Therapeutics is facing intense scrutiny and negative sentiment after voluntarily pausing its Phase 3 HERO trial for ARD-101 due to reversible cardiac safety signals observed in high-dose studies. The community is expressing significant concern about the drug's future and the company's prospects in the competitive Prader-Willi Syndrome treatment landscape.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is a focal point of intense market and social media discussion following significant military action against Iran, including the reported death of its Supreme Leader, as investors and community members weigh the geopolitical implications and ongoing controversies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Fractyl Health, Inc. (GUTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Fractyl Health (GUTS) Projected to Post Quarterly Earnings on Monday

Fractyl Health (NASDAQ:GUTS) will be releasing its Q4 2025 earnings before the market opens on Monday, March 2. (View Earnings Report at...

Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Increases By 22.6%

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 14,901,084 shares, a growth...

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have received a consensus rating of "Hold" from the five brokerages that are currently covering the firm, Marketbeat.com reports. One...

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights GUTS

The DJS Law Group announces that it is investigating claims on behalf of investors of Fractyl Health, Inc. (Fractyl Health or the Company) (NASDAQ: GUTS) for violations of the securities laws...

Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain

Fractyl Health (NASDAQ:GUTS) presented prospective, randomized, double-blind, controlled six-month data from its REMAIN-1 midpoint cohort pilot study, highlighting results the company said support...

<ul class="summary-bullets"><li>The results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial.&nbsp;</li><li>Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles.</li><li>Patient-reported outcomes also indicated reduced cravings for sweet foods.</li></ul>Fractyl Health, Inc. (GUTS) announced on Thursday positive six-month findings from its ongoing REMAIN-1 Midpoint Cohort, a study evaluating Revita for weight maintenance after patients discontinue GLP-1 therapy.The six-month data, covering 40 participants, suggest that Revita helps limit weight regain following GLP-1 discontinuation, with treated patients regaining 4.5% of weight versus 7.5% in the sham group.<h2 class="st-heading-2">Midpoint Study Shows Promising Results</h2>An exploratory analysis of those who lost above-median weight during the GLP-1 run-in showed a 70% relative reduction in post-GLP-1 weight regain for Revita-treated participants compared with sham.&nbsp;These results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial. Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles, including higher HDL cholesterol and a lower triglyceride-to-HDL ratio.&nbsp;Patient-reported outcomes also indicated reduced cravings for sweet foods, suggesting that the device may influence appetite and metabolism through gut-mediated mechanisms.However,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">Fractyl Health's stock</a> plummeted 63% in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React</h2>Despite the fall in the stock’s price, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_29_085922_png_07f795b807.webp" alt="GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits" width="930" height="110"><figcaption>GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said the product that reduces sweet cravings could be extremely profitable, highlighting huge market potential.<stembedurl>https://stocktwits.com/BioRich/message/643264512</stembedurl>Another user said they trusted the management and would hold the stock.&nbsp;<stembedurl>https://stocktwits.com/CocoPeechu/message/643264755</stembedurl>Revita, the main product from Fractyl Health, is meant to reshape the lining of the small intestine through a single, minimally invasive procedure. The FDA has granted Revita Breakthrough Device designation to help people maintain weight after stopping GLP-1 treatments.The company also outlined upcoming catalysts, including one‑year cohort readouts and pivotal REMAIN‑1 data later this year, which could support a future U.S. marketing application.GUTS stock has declined by over 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-now-stock-is-falling/cmyifBjR4KZ">NOW Stock Falls 9% After Q4 Beat: Why Have Analysts Cut Price Targets?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? 

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.

Equity

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.


HC Wainwright Forecasts Fractyl Health FY2030 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Fractyl Health in a research report issued to clients and investors on...

Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Expands By 24.0%

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 11,893,654 shares, a growth...

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, MarketBeat reports. One...

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Fractyl Health Inc.

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

GUTS
Fractyl Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GUTS News

GUTSFractyl Health Inc.